Very low enalapril and enalaprilat exposure via human milk: a case report from the ConcePTION project
These data support evidence of minimal transfer of enalapril and enalaprilat into human milk, suggesting low risk to breastfed infants, and may help address uncertainties in current clinical guidelines. This case report provides detailed maternal pharmacokinetic data for both compounds in human milk, alongside estimated infant exposure at 3 months postpartum.
Authors
- Anne Smits
- Siemon De Nys (ORCID: https://orcid.org/0000-0003-1201-1367)
- Michael Ceulemans (ORCID: https://orcid.org/0000-0002-4130-5869)
- Nina Nauwelaerts (ORCID: https://orcid.org/0000-0001-5301-6813)
- Pieter Annaert (ORCID: https://orcid.org/0000-0003-3525-7351)
- Kristel Van Calsteren (ORCID: https://orcid.org/0000-0002-2438-6783)
- Kathleen Claes
- Karel Allegaert (ORCID: https://orcid.org/0000-0001-9921-5105)
- Martje Van Neste (ORCID: https://orcid.org/0000-0002-0424-450X)
- Emily Jacobs
Institutions
- Uppsala University Hospital (SE)
- Cenovus Energy (Canada) (CA)
- American Pharmacists Association (US)
- Erasmus MC (NL)
- Research Foundation - Flanders (BE)
- Youth Development (US)
- Kindeva Drug Delivery (United States) (US)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/fphar.2025.1727499
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00